Assignee
COMPASS THERAPEUTICS LLC
US·15 granted patents·10 pending applications·60 citations·filing 2016–2025
Top patents by PatentIndex Score
25 records- 0196US10716851B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted Jul 21, 2020·10 cites·5 claims
- 0296US10350292B1Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Granted Jul 16, 2019·12 cites·28 claims
- 0396US10279039B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted May 7, 2019·10 cites·20 claims
- 0496US10279038B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted May 7, 2019·11 cites·16 claims
- 0596US10279040B1Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted May 7, 2019·10 cites·20 claims
- 0695US10434175B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Granted Oct 8, 2019·5 cites·20 claims
- 0787US2024181050A1Agonist antibodies that bind human cd137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2023·Application pending·0 cites
- 0886US2026085121A1Multispecific binding constructs against checkpoint molecules and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2025·Application pending·0 cites
- 0985US11970538B2Multispecific binding constructs against checkpoint molecules and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2021·Granted Apr 30, 2024·1 cites·23 claims
- 1082US12503511B2Multispecific binding constructs against checkpoint molecules and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2024·Granted Dec 23, 2025·0 cites·16 claims
- 1180US12286483B2Method of treating cancer using CD137 antibodies and PD-1 antagonistsCOMPASS THERAPEUTICS LLC·Filed 2023·Granted Apr 29, 2025·0 cites·22 claims
- 1278US11046769B2Multispecific binding constructs against checkpoint molecules and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Granted Jun 29, 2021·1 cites·22 claims
- 1378US2020046833A1Agonist antibodies that bind human cd137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Application pending·0 cites
- 1475US11752207B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2020·Granted Sep 12, 2023·0 cites·13 claims
- 1570US11718679B2CD137 antibodies and PD-1 antagonists and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted Aug 8, 2023·0 cites·28 claims
- 1670US2025313645A1Cd137 antibodies and pd-1 antagonists and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2025·Application pending·0 cites
- 1763US12467062B2Transgenic mouse expressing common human light chainCOMPASS THERAPEUTICS LLC·Filed 2019·Granted Nov 11, 2025·0 cites·26 claims
- 1854US12460004B2Antibodies that bind CD277 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Granted Nov 4, 2025·0 cites·12 claims
- 1952US2020079867A1Compositions and methods for enhancing the killing of target cells by nk cellsCOMPASS THERAPEUTICS LLC·Filed 2019·Application pending·0 cites
- 2049US11851497B2CD137 antibodies and tumor antigen-targeting antibodies and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted Dec 26, 2023·0 cites·11 claims
- 2145US2020109195A1Compositions and methods for enhancing the killing of target cells by nk cellsCOMPASS THERAPEUTICS LLC·Filed 2019·Application pending·0 cites
- 2241US2019031785A1Multispecific immunomodulatory antigen-binding constructsCOMPASS THERAPEUTICS LLC·Filed 2017·Application pending·0 cites
- 2339US2022111047A1Formulations of antibodies that bind human cd137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2020·Application pending·0 cites
- 2438US2018318417A1Multispecific immunomodulatory antigen-binding constructsCOMPASS THERAPEUTICS LLC·Filed 2016·Application pending·0 cites
- 2534US2018251548A1Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-betaCOMPASS THERAPEUTICS LLC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when COMPASS THERAPEUTICS LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →